United Therapeutics (UTHR) EBITDA Margin (2009 - 2026)
United Therapeutics (UTHR) reported EBITDA Margin of 41.69% for Q1 2026, down 650.0% on a YoY basis from 7.58% in Q1 2025, and down 7.65% sequentially from 45.14% in Q4 2025.
United Therapeutics (UTHR) EBITDA Margin (2009 - 2026) Analysis & Trends
United Therapeutics (UTHR) has 18 years of EBITDA Margin data on file, last reported at 41.69% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 650.0% year-over-year to 41.69%; the trailing twelve-month figure through Mar 2026 stood at 45.29% (down 159.0% YoY), and the FY2025 full-year result was 46.89%, down 96.0% from the prior year.
- EBITDA Margin retreated to 41.69% in Q1 2026, from 45.14% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 62.35% in Q1 2022 to a low of 35.73% in Q4 2022.
- A 5-year average of 48.7% and a median of 48.19% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin surged 7944 bps in 2022 and tumbled 785 bps in 2024, its largest moves.
- Tracing UTHR's EBITDA Margin over 5 years: stood at 35.73% in 2022, then climbed by 18 bps to 42.31% in 2023, then grew by 15 bps to 48.61% in 2024, then declined by 7 bps to 45.14% in 2025, then retreated by 8 bps to 41.69% in 2026.
- Business Quant data shows UTHR's EBITDA Margin at 41.69% in Q1 2026, 45.14% in Q4 2025, and 48.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 8.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.69% |
| Dec 31, 2025 | 45.14% |
| Sep 30, 2025 | 48.59% |
| Jun 30, 2025 | 45.64% |
| Mar 31, 2025 | 48.19% |
| Dec 31, 2024 | 48.61% |
| Sep 30, 2024 | 45.81% |
| Jun 30, 2024 | 44.75% |
| Mar 31, 2024 | 52.57% |
| Dec 31, 2023 | 42.31% |
| Sep 30, 2023 | 53.66% |
| Jun 30, 2023 | 52.54% |
| Mar 31, 2023 | 56.11% |
| Dec 31, 2022 | 35.73% |
| Sep 30, 2022 | 60.91% |
| Jun 30, 2022 | 43.22% |
| Mar 31, 2022 | 62.35% |
| Dec 31, 2021 | 40.90% |
| Sep 30, 2021 | 51.43% |
| Jun 30, 2021 | 49.76% |